Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.

Detalhes bibliográficos
Autores:	Pérez de Llano, Luis A., Cosio, Borja G., Domingo, Christian, Urrutia, Isabel, Bobolea, Irina, Valero, Antonio, Entrenas Costa, Luis M., Quirce, Santiago, Barranco, Pilar, Malanda, Nuria Marina, Prieto Andrés, Luis, Álvarez Gutiérrez, Francisco Javier
Tipo de documento:	artigo
Estado:	Versão publicada
Data de publicação:	2019
País:	España
Recursos:	Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:digital.csic.es:10261/213892
Acesso em linha:	http://hdl.handle.net/10261/213892
Access Level:	Acceso aberto
Palavra-chave:	Asthma Asthma management Severe asthma Omalizumab Reslizumab

Descrição
Resumo:	[Background] Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies.